TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent
Year: 2026
Type: article
Abstract: Survival outcome among 82 Mayo Clinic patients with blast/accelerated phase myeloproliferative neoplasm (MPN-BP/AP).
Source: American Journal of Hematology
DOI: 10.1002/ajh.70248
Authors: Naseema Gangat, Momna Warraich, Sudhesh Kumar, Mahnoor Fatima, Kristen McCullough, Kebede H. Begna, Aref Al‐Kali, Mrinal M. Patnaik, William J. Hogan, Abhishek Mangaonkar, Antoine N. Saliba, Mehrdad Hefazi Torghabeh, Hassan Alkhateeb, Mithun V. Shah, James M. Foran, Talha Badar, Jeanne M. Palmer, Cecilia Arana Yi, Animesh Pardanani, Ayalew Tefferi
Institutions: Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic in Arizona
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7130514097